key: cord-0702898-z6un48bf
authors: POMMERET, F.; COLOMBA, J.; BIGENWALD, C.; LAPARRA, A.; BOCKEL, S.; BAYLE, A.; MICHOT, J.-M.; HUESO, T.; ALBIGES, L.; TIBERGHIEN, P.; MAROT, S.; JARY, A.; LACOMBE, K.; F.BARLESI; GRISCELLI, F.; COLOMBA, E.
title: Bamlivimab + etesevimab therapy induces SARS-COV-2 immune escape mutations and secondary clinical deterioration in Covid-19 patients with B cell malignancies
date: 2021-08-02
journal: Ann Oncol
DOI: 10.1016/j.annonc.2021.07.015
sha: edfb10ce44d858b19b6c1e955ef60fbe8ffc1c5f
doc_id: 702898
cord_uid: z6un48bf

nan

Bamlivimab and etesevimab are IgG1 monoclonal antibodies (mAbs), that bind to SARS-Cov2 Spike receptor-binding domain. Treatment with bamlivimab 2800mg and etesevimab 2800mg has been shown to significantly reduce SARS-CoV-2 viral load at day 11 in mild to moderate COVID-19 patients (1) . In the phase 3 part of the BLAZE-1 trial, the risk of Covid-related hospitalization or death was reduced by 70% in patients treated with this combination versus placebo (2).

Subsequently, a temporary use authorization for bamlivimab 700 mg and etesevimab 1400mg association was approved in France to treat patients presenting with high risk of developing severe COVID19 infection. Therefore, we treated 34 cancer patients presenting with a mild to moderate form of SARS-Cov-2 infection and no need for oxygen therapy, within 5 days of their first symptoms, with bamlivimab 700mg plus etesevimab 1400mg. Median age was 62.5

[31 -83] years old. Most patients presented with a solid tumor (N=24, 71%); 10 (29%) had hematological malignancies and 47.1% were receiving chemotherapy.

COVID-19 outcomes were mostly favorable with supplemental oxygenation in only 29% patients versus 41% in our historical cohort (unpublished results). Two patients died from COVID-19 pneumonia but were found out afterwards to be infected by variants with the Spike E484K mutation. These favorable issues were correlated with increasing cycle threshold of nasopharyngeal PCR over time (Fig.1) .

Strikingly, we noticed that patients with B cell malignancies (N=5, 15%) displayed a worse clinical evolution, with delayed COVID-19 symptoms from day 14 to day 30 following the Mabs therapy. All of them needed to be hospitalized again after day 14.

We performed viral Spike gene sequencing on pre-and post-bitherapy nasopharyngeal swabs. Four of these 5 patients acquired a mutation in the receptor binding domain: 3 had a Q493R mutation and 1 had a E484D mutation. Those 5 patients were rescued with convalescent plasmatherapy: 4 patients recovered and were consequently discharged, and one died from COVID-19.

Hematological malignancies patients present high risk of developing severe COVID-19, due to the inherent immune defect caused by the disease and therapy. In a meta- 

Effect of Bamlivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial

Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients

CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer

Bamlivimab treatment leads to rapid selection of immune escape variant carrying E484K mutation in a B.1.1.7 infected and immunosuppressed patient

Tackling COVID-19 with neutralizing monoclonal antibodies

Severe COVID-19 in patients with hematological cancers presenting with viremia